Skip to main content

Advertisement

SpringerLink
Log in

When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacy

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Thrombotic Microangiopathy (TMA) is a heterogeneous collection of syndromes that encompasses TTP, HUS, and other processes characterized by thrombocytopenia, microangiopathic hemolytic anemia, and, if untreated, organ failure and death. Novel therapies have recently been approved for the management of certain thrombotic microangiopathies, including caplacizumab for immune-mediated TTP, and eculizumab for atypical HUS. These options have complicated the standard workflow, which includes initiation of plasma exchange until ADAMTS13 testing can be resulted. Given such results may take several days, there is indecision regarding the appropriate initial management of TMA. Decisions regarding caplacizumab and eculizumab are complex, and include considerations over costs, side effects, and efficacy. In the following forum, we discuss the current data and pose possible management strategies in patients with TMA before final diagnosis can be obtained.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Shatzel J, Taylor JA (2017) Syndromes of thrombotic microangiopathy. Med Clin North Am 101:395–415

    Article  Google Scholar 

  2. Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl PK, Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335–346

    Article  CAS  Google Scholar 

  3. Davio K (2019) FDA Approves the First Drug Specifically Indicated for aTTP. AJMC Managed Markets Network. p 7 of 9. http://www.ajmc.com. Accessed 16 Nov 2019

  4. Bendapudi P, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, Sun L, Upadhyay V, Hamdan A, Brunner AM, Gansner JM, Viswanathan S, Kaufman RM, Uhl L, Stowell CP, Dzik WH, Makar RS (2017) Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Hematol 4:e157–e164

    Article  Google Scholar 

  5. Li A, Khalighi PR, Wu Q, Garcia DA (2018) External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 16(1):164–169

    Article  CAS  Google Scholar 

  6. Kim CH, Simmons SC, Williams LA III, Staley EM, Zheng XL, Pham HP (2017) ADAMST13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis. Transfusion 57(11):2609–2618

    Article  Google Scholar 

  7. Legendre C, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181

    Article  CAS  Google Scholar 

  8. Herper M (2010) The world’s most expensive drugs. Forbes. http://www.forbes.com. Accessed 8 Jan 2019

  9. McKeage K (2019) Ravulizumab: first global approval. Drugs 79(3):347–352

    Article  CAS  Google Scholar 

  10. Go RS, Winters JL, Leung N et al (2016) Thrombotic microangiopathy care pathway: a consensus statement for the mayo clinic complement alternative pathway-thrombotic microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc 91(9):1189–1211

    Article  Google Scholar 

  11. Smock KJ (2016) The Role of ADAMTS13 testing in the work up of suspected thrombotic thrombocytopenic purpura. AACC

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Oregon Health & Science University, Knight Cancer Institute, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA

    Catherine R. Murphree, Sven R. Olson, Thomas G. DeLoughery & Joseph J. Shatzel

Authors
  1. Catherine R. Murphree
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sven R. Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas G. DeLoughery
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph J. Shatzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine R. Murphree.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murphree, C.R., Olson, S.R., DeLoughery, T.G. et al. When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacy. J Thromb Thrombolysis 49, 602–605 (2020). https://doi.org/10.1007/s11239-020-02094-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-020-02094-8

Keywords

Search

Navigation